Proxy Report 07/06/2018
In general, TiGenix is in compliance with the Belgian regulations relating to the organisation and procedures of the Annual General Meeting. Under ITEM 4, the board of directors seeks approval of the Company's remuneration report. Since ECGS does not approve of LT incentive plans that do not operate one or more challenging performance conditions, it recommends to vote OPPOSE. On January 5, 2018, TiGenix announced an offer by Japan-based Takeda Pharmaceuticals Company Ltd, to acquire all its outstanding shares at a price of EUR 1.78 per share, which represents an enterprise value of approximately EUR 488 million.
TiGenix develops and commercializes cell therapy products. Co.'s stem cell programs are based on a validated platform of allogeneic expanded adipose-derived stem cells (eASC) targeting autoimmune and inflammatory diseases. Co.'s main product, ChondroCelect, is a cell-based product that is used for cartilage repair in the knee. Co.'s is also involved in developing Cx601, which is in Phase III clinical trial for the treatment of complex perianal fistulas in patients suffering from Crohn's disease; Cx611, which has completed a Phase IIa clinical trial for the treatment of rheumatoid arthritis; and Cx621, which has completed a Phase I trial for the treatment of autoimmune diseases.
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.